SCHEMBL2426587

SCHEMBL2426587

COC(=O)[C@@H](NC(=O)OC(C)(C)C)c1ccc(OC)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.50
CTSS P25774 1/20 0.50
CTSK P43235 1/20 0.50
ATM Q13315 1/20 0.47
ABCB1 P08183 1/20 0.46
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
S1PR3 Q99500 1/20 0.44
TACR3 P29371 2/20 0.44
CACNA1B Q00975 1/20 0.43
MAPT P10636 1/20 0.41
FAAH O00519 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13808330 1.00 NPSR1 (0.50) NPSR1CTSSCTSKATMABCB1
SCHEMBL2426585 1.00 NPSR1 (0.50) NPSR1CTSSCTSKATMABCB1
SCHEMBL16171651 0.90 NPSR1 (0.51) NPSR1CTSSCTSKATMABCB1
SCHEMBL16174110 0.90 NPSR1 (0.51) NPSR1CTSSCTSKATMABCB1
SCHEMBL844432 0.88 ATM (0.56) NPSR1CTSSCTSKATMABCB1
SCHEMBL844431 0.88 ATM (0.56) NPSR1CTSSCTSKATMABCB1
SCHEMBL1115110 0.88 NPSR1 (0.50) NPSR1CTSSCTSKATMABCB1
SCHEMBL3217896 0.88 ATM (0.56) NPSR1CTSSCTSKATMABCB1
SCHEMBL15258990 0.88 CTSS (0.48) NPSR1CTSSCTSKATMABCB1
SCHEMBL14254331 0.87 CTSS (0.48) CTSSCTSKPPARGPPARAS1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025243042-A1 COMPOUNDS FOR THE INHIBITION OF CYCLOPHILIN D THE UNIVERSITY OF LIVERPOOL (GB) 2025-11-27 WO disclosed
US-20130303547-A1 HCV Protease Inhibitors and Uses Thereof ABBVIE INC (US) 2013-11-14 US disclosed
US-8497275-B2 HCV protease inhibitors and uses thereof ABBVIE INC. (US) 2013-07-30 US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
US-20100029686-A1 HCV PROTEASE INHIBITORS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-02-04 US disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303547-A1 HCV Protease Inhibitors and Uses Thereof SERPINB1, PEPD, PREP NPSR1 3132/4885CTSS 40/4885CTSK 86/4885
US-20100029686-A1 HCV PROTEASE INHIBITORS AND USES THEREOF SERPINB1, PEPD, PREP NPSR1 3132/4885CTSS 40/4885CTSK 86/4885
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 NPSR1 180/4885CTSS 1478/4885CTSK 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.